 SOUTH SAN FRANCISCO, Calif., June 14, 2021 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization BIO Board of Directors for the 2021-2022 term. 